Paul Conyngham wasn't supposed to be in the veterinary oncology business. The Australian AI entrepreneur had built his career in machine learning and data science, co-founding Core Intelligence. Then Rosie got sick.
Rosie—Conyngham's dog—was diagnosed with cancer. Rather than accept the limited treatment options, Conyngham did what technologists sometimes do when confronted with impossible problems: he engineered a solution. Working alongside scientists at UNSW's RNA Institute and the Ramaciotti Centre for Genomics, he designed a personalized mRNA cancer vaccine, using AI to hunt for tumor-specific targets hiding in Rosie's genome.
According to the company, the tumor shrank by roughly 75%. Rosie lived two more years.
That outcome, however bittersweet, became the proof of concept for Gamgee, a San Francisco-based startup that Conyngham launched to offer the same bespoke vaccine approach to other pet owners facing similar heartbreak. Backed by Y Combinator and investors including Founders Fund, Golden Gate Ventures, and Atypical Ventures, the company is now enrolling dogs in clinical trials for what it describes as the first personalized cancer treatment protocol designed specifically for canines.
Whether that claim holds up—and whether this approach can leap from a single case to a scalable veterinary product—remains very much an open question.
Manufacturing Hope, One Dog at a Time
Gamgee's process mirrors, in miniature, the cutting-edge human cancer therapies being pursued by companies like BioNTech and Genentech. It starts with a tissue sample collected at a local vet clinic, then shipped to sequencing partners for whole exome analysis. The goal: identify the genetic mutations fueling that particular cancer. AI algorithms sift through the data, ranking potential neoantigen targets—proteins that appear only on cancer cells, not healthy tissue. A design report gets generated for clinician review. Then comes GMP manufacturing and cold-chain delivery, with veterinary oncologists administering the vaccine on a labeled schedule.
Turnaround time, according to the company, runs about four weeks from initial sample. The product designation—ze-ets-001—suggests a regulatory pathway still taking shape. (Australia's veterinary medicines authority, APVMA, published guidance in recent years noting it was developing a framework for veterinary mRNA vaccines, an acknowledgment that the rules for these products remain in flux.)
Current pricing? Undisclosed. Manufacturing capacity? Also undisclosed. Gamgee has outlined long-term goals: 24-hour vaccine production and a $2,000-per-vaccine price point. But those remain aspirations rather than realities, at least for now.
The company operates with a small team—two employees, according to its Y Combinator listing—and is running clinical trials in Australia while accepting applications from pet owners globally. How it coordinates logistics across continents with such lean staffing is one of those startup mysteries that founders tend to answer with phrases like "scrappiness" and "tight partnerships." In Gamgee's case, those partnerships include UNSW's RNA Institute, the Ramaciotti Centre for Genomics, and the University of Queensland.
A Crowded Field, Different Bets
Gamgee isn't entering an empty market. Veterinary precision oncology has attracted a cluster of startups, each placing different bets on how to translate genomics into better outcomes.
One Health Company's FidoCure uses tumor genomics to recommend targeted therapies from existing drugs—essentially, matching dogs to medications already approved for other uses. ImpriMed offers AI-driven predictions of how individual tumors might respond to various chemotherapy agents. Ardent Animal Health is testing autologous tumor vaccines (non-mRNA) paired with checkpoint modulators. Anivive Lifesciences provides genomic profiling to guide treatment decisions.
Gamgee, by contrast, manufactures individualized mRNA vaccines for each patient. It's a harder technical challenge—custom biologics rather than repurposed pills—and potentially a harder business model. Manufacturing vaccines one at a time doesn't benefit from economies of scale the way traditional pharmaceuticals do. And while the approach has shown promise in human trials, translating that to veterinary medicine introduces new wrinkles: different regulatory frameworks, different cost sensitivities, different client expectations.
Then again, the market is enormous. Fortune Business Insights pegs the veterinary oncology market at $2.90 billion currently, with growth projected through the next decade. In the U.S. alone, roughly six million dogs are diagnosed with cancer each year, according to the Animal Cancer Foundation and the American Kennel Club. Of those, only about 200,000 to 250,000 receive chemotherapy annually, per Brakke Consulting data submitted to the FDA.
That gap—between diagnosed and treated—suggests either unmet demand or prohibitive cost. Gamgee is wagering it can address both.
From Media Storm to Clinical Validation
Conyngham's story hit the media circuit hard. UNSW profiled Rosie's case in early coverage; then NBC's TODAY show picked it up, followed by CBS News, Fortune, and ABC News Australia. By mid-summer, Conyngham had announced Gamgee's acceptance into Y Combinator.
The arc is familiar in startup circles: personal crisis, technical breakthrough, media attention, accelerator validation, investor interest. But the next chapter—the one where clinical trials deliver data, regulatory approvals come through (or don't), and the business model either scales or stalls—is always the hardest to write.
Gamgee describes its Australian trial as "currently enrolling," though no identifier appears in public registries like ANZCTR or ClinicalTrials.gov. That's not necessarily unusual for early-stage veterinary trials, which face different disclosure requirements than human studies. Still, it leaves observers with limited visibility into patient numbers, endpoints, or timelines.
The company's website solicits partnerships with veterinary oncologists, computational biologists, RNA scientists, manufacturing specialists, universities running trials, and companies building "AI-native scientific systems"—a wishlist that suggests Gamgee is still assembling the pieces.
The N-of-1 Problem
Rosie's outcome offers proof that bespoke cancer vaccines can work in dogs. But translating an N-of-1 success into a validated, repeatable protocol is where most personalized medicine efforts stumble. The variability is enormous: different cancers, different breeds, different immune systems, different starting points in disease progression.
Gamgee will need to show that its AI-driven target selection works across a heterogeneous patient population, that the vaccines are safe and effective in controlled settings, and that the economics make sense for veterinarians, pet owners, and insurers (a small but growing part of the veterinary landscape). The company will also need to navigate regulatory pathways that are, frankly, still being written.
Perhaps the most difficult question is one of expectations. Pet owners facing a cancer diagnosis are often desperate, willing to try anything that offers hope. Building a business on that desperation is ethically fraught—startups in this space have to balance optimism with honesty about what the science can and cannot yet deliver.
For now, Gamgee is focused on enrollment, refining its platform, and moving toward data that might answer some of these questions. The company has funding, technical partnerships, and a founder with both the motivation and the expertise to push forward. Whether that's enough to turn one dog's story into a new standard of care is the gamble investors are making.
In the meantime, Rosie's legacy is this: a startup, a clinical trial, and a room full of pet owners hoping for the same outcome Conyngham got—just a little more time.
